Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Primary research

DEPDC1B collaborates with GABRD to regulate ESCC progression

Authors: Yunfeng Yuan, Wei Ping, Ruijie Zhang, Zhipeng Hao, Ni Zhang

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is the leading cause of cancer-related death worldwide with a poor prognosis. Given that DEPDC1B plays a key role in multiple cancers, the role of this molecule in ESCC was explored to identify potential targets for ESCC patients.

Method

The expression level of DEPDC1B in ESCC was revealed based on the TCGA database and immunohistochemical experiments on clinical tissues. The correlation between DEPDC1B and survival of ESCC patients was analyzed by Kaplan–Meier method. Small hairpin RNA (shRNA)-mediated silencing of DEPDC1B expression in ESCC cells and performed a series of in vitro and in vivo functional validations.

Result

DEPDC1B was overexpressed in ESCC. High expression of DEPDC1B was significantly negatively correlated with overall survival in patients with ESCC. Moreover, knockdown of DEPDC1B inhibited ESCC cell proliferation, clone formation, migration, tumor formation and promoted apoptosis. Furthermore, knockdown of DEPDC1B leaded to significant downregulation of GABRD in ESCC cells. Meanwhile, GABRD expression was upregulated in ESCC, and its silencing can inhibit the proliferation and migration of the tumor cells. Interestingly, there was a protein interaction between DEPDC1B and GABRD. Functionally, GABRD knockdown partially reversed the contribution of DEPDC1B to ESCC progression. In addition, GABRD regulated ESCC progression may depend on PI3K/AKT/mTOR signaling pathway.

Conclusion

DEPDC1B collaborated with GABRD to regulate ESCC progression, and inhibition of this signaling axis may be a potential therapeutic target for ESCC.

Available only for authorised users

DiSiena M, Perelman A, Birk J, Rezaizadeh H. Esophageal cancer: an updated review. South Med J. 2021;114(3):161–8.CrossRefPubMed

Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7.CrossRefPubMed

Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A, et al. Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 2019;144:95–135.CrossRefPubMed

Yuequan J, Shifeng C, Bing Z. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg. 2010;90(3):908–13.CrossRefPubMed

Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.CrossRef

Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46(10):1097–102.CrossRefPubMed

Guo W, Wang P, Li N, Shao F, Zhang H, Yang Z, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget. 2018;9(17):13920–33.CrossRefPubMed

Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, et al. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2017;8(5):8315–29.CrossRefPubMed

Marchesi S, Montani F, Deflorian G, D’Antuono R, Cuomo A, Bologna S, et al. DEPDC1B coordinates de-adhesion events and cell-cycle progression at mitosis. Dev Cell. 2014;31(4):420–33.CrossRefPubMedPubMedCentral

10.

Figeac N, Pruller J, Hofer I, Fortier M, OrtusteQuiroga HP, Banerji CRS, et al. DEPDC1B is a key regulator of myoblast proliferation in mouse and man. Cell Prolif. 2020;53(1): e12717.CrossRefPubMed

11.

Su YF, Liang CY, Huang CY, Peng CY, Chen CC, Lin MC, et al. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK. J Biomed Sci. 2014;21:67.CrossRefPubMedPubMedCentral

12.

Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2014;450(1):899–905.CrossRefPubMed

13.

Consonni SV, Maurice MM, Bos JL. DEP domains: structurally similar but functionally different. Nat Rev Mol Cell Biol. 2014;15(5):357–62.CrossRefPubMed

14.

Boudreau HE, Broustas CG, Gokhale PC, Kumar D, Mewani RR, Rone JD, et al. Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. Int J Mol Med. 2007;19(1):29–39.PubMed

15.

Peck J, Douglas Gt WuCH, Burbelo PD. Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. FEBS Lett. 2002;528(1–3):27–34.CrossRefPubMed

16.

Bai S, Chen T, Du T, Chen X, Lai Y, Ma X, et al. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. Oncol Lett. 2017;14(6):6801–8.PubMedPubMedCentral

17.

Lai CH, Xu K, Zhou J, Wang M, Zhang W, Liu X, et al. DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. Cell Death Dis. 2020;11(11):986.CrossRefPubMedPubMedCentral

18.

Pollino S, Benassi MS, Pazzaglia L, Conti A, Bertani N, Righi A, et al. Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas. Histol Histopathol. 2018;33(6):597–608.PubMed

19.

Xu Y, Sun W, Zheng B, Liu X, Luo Z, Kong Y, et al. DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Exp Cell Res. 2019;379(1):48–54.CrossRefPubMed

20.

Zhao H, Yu M, Sui L, Gong B, Zhou B, Chen J, et al. High expression of DEPDC1 promotes malignant phenotypes of breast cancer cells and predicts poor prognosis in patients with breast cancer. Front Oncol. 2019;9:262.CrossRefPubMedPubMedCentral

21.

Dang XW, Pan Q, Lin ZH, Wang HH, Li LH, Li L, et al. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. Aging (Albany NY). 2021;13(16):20094–115.CrossRef

22.

Wang L, Tang L, Xu R, Ma J, Tian K, Liu Y, et al. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5. Cell Death Dis. 2021;12(8):753.CrossRefPubMedPubMedCentral

23.

Jawhar NM. Tissue microarray: a rapidly evolving diagnostic and research tool. Ann Saudi Med. 2009;29(2):123–7.CrossRefPubMedPubMedCentral

24.

Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–89.PubMed

25.

Fan X, Wen J, Bao L, Gao F, Li Y, He D. Identification and validation of DEPDC1B as an independent early diagnostic and prognostic biomarker in liver hepatocellular carcinoma. Front Genet. 2021;12: 681809.CrossRefPubMed

26.

Sun Y, Zhang Z. In silico identification of crucial genes and specific pathways in hepatocellular cancer. Genet Test Mol Biomarkers. 2020;24(5):296–308.CrossRefPubMed

27.

Zhang S, Shi W, Hu W, Ma D, Yan D, Yu K, et al. DEP domain-containing protein 1B (DEPDC1B) promotes migration and invasion in pancreatic cancer through the Rac1/PAK1-LIMK1-cofilin1 signaling pathway. Onco Targets Ther. 2020;13:1481–96.CrossRefPubMedPubMedCentral

28.

Feng Y, Kapornai K, Kiss E, Tamas Z, Mayer L, Baji I, et al. Association of the GABRD gene and childhood-onset mood disorders. Genes Brain Behav. 2010;9(6):668–72.PubMedPubMedCentral

29.

Dibbens LM, Feng HJ, Richards MC, Harkin LA, Hodgson BL, Scott D, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet. 2004;13(13):1315–9.CrossRefPubMed

30.

Gross AM, Kreisberg JF, Ideker T. Analysis of matched tumor and normal profiles reveals common transcriptional and epigenetic signals shared across cancer types. PLoS ONE. 2015;10(11): e0142618.CrossRefPubMedPubMedCentral

31.

Niu G, Deng L, Zhang X, Hu Z, Han S, Xu K, et al. GABRD promotes progression and predicts poor prognosis in colorectal cancer. Open Med (Wars). 2020;15(1):1172–83.CrossRef

32.

Wu M, Kim KY, Park WC, Ryu HS, Choi SC, Kim MS, et al. Enhanced expression of GABRD predicts poor prognosis in patients with colon adenocarcinoma. Transl Oncol. 2020;13(12): 100861.CrossRefPubMedPubMedCentral

33.

Purwana I, Zheng J, Li X, Deurloo M, Son DO, Zhang Z, et al. GABA promotes human beta-cell proliferation and modulates glucose homeostasis. Diabetes. 2014;63(12):4197–205.CrossRefPubMed

34.

Xu J, Li C, Yin XH, Zhang GY. Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology. 2008;54(7):1029–40.CrossRefPubMed

Title: DEPDC1B collaborates with GABRD to regulate ESCC progression
Authors: Yunfeng Yuan
Wei Ping
Ruijie Zhang
Zhipeng Hao
Ni Zhang
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02593-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy

Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated

Cell senescence-associated genes predict the malignant characteristics of glioblastoma

Role of CC-chemokine ligand 2 in gynecological cancer

A review on the role of LINC00467 in the carcinogenesis

Integrated analysis to identify the AC005154.6/hsa-miR-29c-3p/CCNL2 axis as a novel prognostic biomarker associated with immune infiltration in prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer